James Kyle Bryan
No más puestos en curso
Perfil
James Kyle Bryan worked as a Director of Clinical Research at Poniard Pharmaceuticals, Inc., Vice President of Global Product Development at Pharmaceutical Product Development LLC, Vice President of Medical Affairs at Seagen Inc., and Chief Medical Officer at VentiRx Pharmaceuticals, Inc. He received his undergraduate and doctorate degrees from Louisiana State University.
Antiguos cargos conocidos de James Kyle Bryan.
Empresas | Cargo | Fin |
---|---|---|
Pharmaceutical Product Development LLC
Pharmaceutical Product Development LLC Miscellaneous Commercial ServicesCommercial Services Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC. | Corporate Officer/Principal | - |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Chief Tech/Sci/R&D Officer | - |
PONIARD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
SEAGEN INC. | Chief Tech/Sci/R&D Officer | - |
Formación de James Kyle Bryan.
Louisiana State University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
PONIARD PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Pharmaceutical Product Development LLC
Pharmaceutical Product Development LLC Miscellaneous Commercial ServicesCommercial Services Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC. | Commercial Services |
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | Health Technology |
- Bolsa de valores
- Insiders
- James Kyle Bryan